Five-year data from the KEYNOTE-942 trial, presented at ASCO 2026, show that intismeran autogene plus Keytruda sustains a 49% reduction in melanoma recurrence risk and drives overall survival to 92.2%…
A landmark phase 3 trial of 4,429 patients showed the Prosigna 50-gene genomic test can safely spare two-thirds of clinically high-risk breast cancer patients from chemotherapy, with equivalent five-year survival…
A bispecific antibody that simultaneously targets PD-1 and VEGF just beat the standard immunotherapy regimen head-to-head in overall survival. It is the first time any drug has achieved this milestone…
A drug whose target and molecule were both conceived by AI just improved lung function in a randomized Nature Medicine trial. Inside AI drug discovery’s 2026 clinical verdict, from Insilico’s…
A Phase III trial presented at ASCO 2026 and simultaneously published in The Lancet shows that pairing a precision TROP2-targeting weapon with the world’s most prescribed immunotherapy rewrites what is…
A Phase 3 trial just cut the risk of death by 60 percent in metastatic pancreatic cancer, a disease that has resisted nearly every therapeutic advance for four decades. The…
At ASCO 2026’s plenary session, ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, cut the risk of death by 34% in advanced squamous NSCLC, becoming the first drug to…
At ASCO 2026, izalontamab brengitecan became the first bispecific antibody-drug conjugate to improve both progression-free and overall survival in triple-negative breast cancer. Inside the EGFRxHER3 mechanism, the Phase 3 trial…
More than thirty targeted protein degraders are now in human trials, with the first Phase 3 readouts arriving in 2026. Inside the vepdegestrant breast cancer data, the BTK degrader race,…
A major study being presented this week at the American Society of Clinical Oncology’s annual meeting found that patients with early-stage cancer who took GLP-1 receptor agonists were 38 to…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.